The American Journal of Managed Care4h
Pursuit of ADCs in Bladder Cancer Comes With Questions About Toxicity, Cost
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care15h
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
UroToday21h
ASCO GU 2025: Evaluating Survival in Aggressive Variant Prostate Cancer Patients Undergoing PSMA Radioligand Therapy
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...
Hosted on MSN21h
Metastasis-Directed Therapy for Prostate Cancer a Clear Winner in Meta-Analysis
Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...
Cure Today22h
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
UroToday23h
ASCO GU 2025: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer with Salvage Surgery
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...